- USDCAD
- XAUUSD
- XAGUSD
- WTI
- USDX
Markets
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests


Central Bank Of Turkey: Turkey's Net External Debt Stock Was $206.73 Billion At The End Of The Third Quarter
UK Office For National Statistics: UK Supermarket Sales Strengthened In October After The Government Advised Buying Durable Goods
According To AmSpec, An Independent Inspection Agency In Malaysia, Malaysia's Palm Oil Exports From November 1 To 20 Totaled 973,805 Tons, A Decrease Of 10.24% Compared To 1,084,928 Tons In The Same Period Last Month
Ding Xuexiang Will Visit Singapore And Chair A Meeting Of The China-Singapore Bilateral Cooperation Mechanism
Viewpoint: Current Short-term Bitcoin Holders Are Realizing An Average Loss Of About 15%, And The SOPR Indicator Is Signaling An Entry Point
Polish Prime Minister Tusk: I Have Received Reports From The Ministers Regarding The Entry Into Polish Airspace; There Is No Threat From The Air
Russian Deputy Foreign Minister Ryabkov Stated That NATO's Granting Of "quasi-member" Status To Ukraine Is Unacceptable
Sri Lanka Central Bank Governor: There Are Many Policies That Affect Economic Growth, Not Just Monetary Policy
The Commander Of The Ukrainian Drone Force Stated That In The Past 50 Days, Ukrainian Drone Forces Have Struck 41 Russian Oil Refineries And Weapons Production Facilities
Sri Lanka Central Bank Governor: A Buffer Mechanism Will Be Established To Cope With Headwinds
Sri Lanka Central Bank Governor: Hope To See The Impact Of The Current Global Oil Price Decline
Hungarian Finance Minister Kármán Stated That A New Medium-term Agreement Is Being Developed To Ensure That Nominal Wages Are Aligned With Economic Performance
Sri Lanka Central Bank Governor: Even With Fuel Subsidies, Inflation Remains Higher Than Expected
Sri Lanka Central Bank Governor: Once Inflation Enters A Downward Trend, The Central Bank Will Return To An Easing Policy
The Governor Of The Central Bank Of Sri Lanka Said That The Reserve Requirement Ratio Will Be Used To Absorb About 150 Billion Rupees Flowing Back To The Central Bank
Sri Lanka Central Bank Governor: Reserve Requirement Ratio Will Help Maintain Short-term Interest Rates
The Governor Of The Central Bank Of Sri Lanka Said He Hopes To Bring The Inflation Rate Down To The Target Level Of 5% As Soon As Possible

Canada Industrial Product Price Index YoY (Oct)A:--
F: --
U.S. Philadelphia Fed Business Activity Index (SA) (Nov)A:--
F: --
P: --
U.S. Initial Jobless Claims 4-Week Avg. (SA)A:--
F: --
U.S. Weekly Continued Jobless Claims (SA)A:--
F: --
U.S. Philadelphia Fed Manufacturing Employment Index (Nov)A:--
F: --
P: --
ECB President Lagarde Speaks
FOMC Member Hammack Speaks
U.S. Conference Board Leading Economic Index MoM (Oct)A:--
F: --
P: --
U.S. Conference Board Lagging Economic Index MoM (Oct)A:--
F: --
P: --
U.S. Conference Board Coincident Economic Index MoM (Oct)A:--
F: --
P: --
U.S. Conference Board Leading Economic Index (Oct)A:--
F: --
P: --
U.S. EIA Weekly Natural Gas Stocks ChangeA:--
F: --
P: --
U.S. Kansas Fed Manufacturing Production Index (Nov)A:--
F: --
P: --
U.S. Kansas Fed Manufacturing Composite Index (Nov)A:--
F: --
P: --
U.S. 10-Year TIPS Auction Avg. YieldA:--
F: --
P: --
Argentina Trade Balance (Oct)A:--
F: --
P: --
Richmond Federal Reserve President Barkin delivered a speech.
South Korea PPI MoM (Oct)A:--
F: --
Richmond Federal Reserve President Barkin delivered a speech.
U.S. Weekly Treasuries Held by Foreign Central BanksA:--
F: --
P: --
Japan National CPI MoM (Oct)A:--
F: --
P: --
Japan National CPI MoM (Not SA) (Oct)A:--
F: --
P: --
Japan National Core CPI YoY (Oct)A:--
F: --
P: --
Japan National CPI YoY (Oct)A:--
F: --
P: --
Philadelphia Fed President Henry Paulson delivers a speech
U.K. GfK Consumer Confidence Index (Nov)A:--
F: --
P: --
China, Mainland 5-Year Loan Prime RateA:--
F: --
P: --
China, Mainland 1-Year Loan Prime Rate (LPR)A:--
F: --
P: --
Turkey Capacity Utilization (Nov)A:--
F: --
P: --
Turkey Consumer Confidence Index (Nov)A:--
F: --
P: --
Germany PPI MoM (Oct)A:--
F: --
P: --
Germany PPI YoY (Oct)A:--
F: --
P: --
U.K. Core Retail Sales YoY (SA) (Oct)A:--
F: --
U.K. Retail Sales MoM (SA) (Oct)A:--
F: --
U.K. Retail Sales YoY (SA) (Oct)A:--
F: --
ECB President Lagarde Speaks
India Industrial Production Index YoY (Oct)--
F: --
P: --
Mexico Retail Sales MoM (Sept)--
F: --
P: --
Canada Core Retail Sales MoM (SA) (Sept)--
F: --
P: --
Canada Retail Sales MoM (SA) (Sept)--
F: --
P: --
U.S. UMich Current Economic Conditions Index Final (Nov)--
F: --
P: --
U.S. UMich 1-Year-Ahead Inflation Expectations Final (Nov)--
F: --
P: --
U.S. UMich Consumer Expectations Index Final (Nov)--
F: --
P: --
U.S. UMich Consumer Sentiment Index Final (Nov)--
F: --
P: --
Euro Zone Consumer Confidence Index Prelim (Nov)--
F: --
P: --
U.S. Weekly Total Oil Rig Count--
F: --
P: --
U.S. Weekly Total Rig Count--
F: --
P: --
Australia Composite PMI Prelim (Nov)--
F: --
P: --
Australia Manufacturing PMI Prelim (Nov)--
F: --
P: --
France Services PMI Prelim (SA) (Nov)--
F: --
P: --
France Manufacturing PMI Prelim (Nov)--
F: --
P: --
France Composite PMI Prelim (SA) (Nov)--
F: --
P: --
Germany Composite PMI Prelim (SA) (Nov)--
F: --
P: --
Germany Services PMI Prelim (SA) (Nov)--
F: --
P: --
Germany Manufacturing PMI Prelim (SA) (Nov)--
F: --
P: --
Euro Zone Composite PMI Prelim (SA) (Nov)--
F: --
P: --
Euro Zone Services PMI Prelim (SA) (Nov)--
F: --
P: --
Euro Zone Manufacturing PMI Prelim (SA) (Nov)--
F: --
P: --
U.K. Composite PMI Prelim (Nov)--
F: --
P: --













































No matching data
Compare the 10 best healthcare ETFs in 2026, including XLV, VHT, IBB, and XBI. Explore expense ratios, holdings, investment strategies, and risks.
Healthcare ETFs range from diversified sector funds to focused biotechnology, pharmaceutical, medical device, and healthcare provider funds. A fund with strong recent returns may also carry concentrated holdings or industry-specific risks. The best choice depends on your investment goals, preferred exposure, and tolerance for volatility.

The following 10 healthcare ETFs cover the main ways to invest in the healthcare industry. Rather than ranking them solely by recent performance, this comparison considers their investment focus, index methodology, and costs.
| ETF | Ticker | Investment Focus | Expense Ratio |
|---|---|---|---|
| Health Care Select Sector SPDR Fund | XLV | Large U.S. healthcare companies | 0.08% |
| Vanguard Health Care ETF | VHT | Broad U.S. healthcare market | 0.09% |
| Fidelity MSCI Health Care Index ETF | FHLC | Broad U.S. healthcare market | 0.084% |
| iShares U.S. Healthcare ETF | IYH | U.S. healthcare companies | 0.37% |
| iShares Biotechnology ETF | IBB | Biotechnology companies | 0.44% |
| SPDR S&P Biotech ETF | XBI | Biotechnology companies | 0.35% |
| iShares U.S. Medical Devices ETF | IHI | Medical device manufacturers | 0.37% |
| VanEck Pharmaceutical ETF | PPH | Pharmaceutical companies | 0.36% |
| iShares U.S. Healthcare Providers ETF | IHF | Healthcare insurers and providers | 0.37% |
| iShares Global Healthcare ETF | IXJ | Global healthcare companies | 0.38% |
Expense ratios reflect the latest available issuer disclosures checked in November 2026. Fees can change, so investors should confirm current figures in each fund's prospectus.
These funds are not direct substitutes. XLV, VHT, FHLC, and IYH provide broad U.S. healthcare exposure, while IBB and XBI concentrate on biotechnology. IHI, PPH, and IHF target specific healthcare industries, and IXJ provides international diversification.
Healthcare includes businesses with very different revenue sources and growth drivers. Choosing a fund by industry exposure can help investors avoid buying a portfolio that does not match their expectations.
These four funds provide exposure to multiple healthcare industries, but their index construction affects which companies receive the most weight.
The main distinction is not simply the number of stocks each fund owns. Their benchmarks determine which companies qualify and how much influence larger holdings have on overall performance.
Biotechnology companies develop drugs, treatments, and other medical technologies. Their business prospects often depend on clinical trial results, regulatory approvals, research funding, and the ability to bring new products to market.
IBB may suit investors who prefer greater exposure to larger biotechnology companies. XBI provides a more balanced allocation across company sizes, but its exposure to smaller businesses can increase sensitivity to financing conditions and clinical trial setbacks.
Investors who want exposure to a particular part of healthcare can use specialized ETFs rather than buying the entire sector.
These ETFs respond to different business drivers. Medical device manufacturers depend on equipment demand and product adoption, pharmaceutical companies rely on drug sales and patent protection, and healthcare providers are more exposed to insurance economics and medical service costs.
The iShares Global Healthcare ETF (IXJ) tracks the S&P Global 1200 Health Care Sector Capped Index. It invests in healthcare companies across the U.S. and international markets, including pharmaceutical manufacturers, biotechnology businesses, and medical equipment companies.
IXJ provides access to companies such as Roche, Novartis, and AstraZeneca alongside U.S. healthcare businesses. However, global exposure does not mean equal geographic allocation. As of November 4, 2026, U.S. companies accounted for about 73% of its portfolio, with Switzerland, the U.K., and Japan among its other major country exposures.
IXJ can help investors diversify beyond U.S.-listed healthcare stocks, although currency movements and different regulatory environments introduce additional risks.
Investors choosing between healthcare ETFs should focus on differences that affect portfolio exposure, not just ticker symbols or historical returns.
| ETF | Market Coverage | Expense Ratio | Main Difference |
|---|---|---|---|
| XLV | S&P 500 healthcare stocks | 0.08% | Focuses on large-cap companies |
| VHT | Large-, mid-, and small-cap U.S. stocks | 0.09% | Broader market coverage |
| FHLC | Large-, mid-, and small-cap U.S. stocks | 0.084% | Broad exposure at a low cost |
| IYH | U.S. large- and mid-cap healthcare stocks | 0.37% | Higher cost for similar broad-sector exposure |
XLV is a straightforward option for investors who want exposure to established S&P 500 healthcare companies. VHT and FHLC cover a wider range of market capitalizations, making them useful alternatives for investors who want exposure to smaller healthcare businesses as well.
VHT and FHLC are particularly close alternatives in terms of broad market coverage, while their fees are also similar. IYH is worth comparing for its index exposure, but its higher expense ratio makes the cost difference important for long-term investors.
The choice between a U.S.-focused fund such as VHT and a global fund such as IXJ depends on how much international exposure you want.
VHT invests in U.S. healthcare companies across different market-cap segments. IXJ includes companies from multiple countries, allowing investors to access international pharmaceutical and medical technology businesses that may not be represented in the same way in a U.S.-only fund.
However, investors should examine IXJ's geographic allocation before assuming it provides balanced global exposure. Its portfolio remains heavily weighted toward U.S. companies, so it adds international holdings without removing most of its U.S. market exposure.
After identifying the type of healthcare exposure you want, compare the costs, underlying holdings, and distribution policies of the available funds.
An expense ratio is the annual operating cost of an ETF, expressed as a percentage of assets. For example, a 0.10% expense ratio costs approximately $10 per year on a $10,000 investment, while a 0.40% ratio costs about $40.
Lower fees can improve long-term results when funds provide similar exposure. Trading liquidity also matters: ETFs with higher trading volume and narrower bid-ask spreads can be cheaper to buy and sell.
Check the fund's largest holdings and how much of the portfolio they represent. A healthcare ETF may hold dozens or hundreds of stocks but still be heavily influenced by a small number of large companies.
Also consider overlap between funds. Holding XLV and VHT together, for example, may add less diversification than expected because both invest in many of the same major U.S. healthcare businesses.
Specialized ETFs can increase exposure to a particular industry, but they also make portfolio results more dependent on that segment.
Many healthcare ETFs distribute dividends, but a higher yield does not automatically make a fund a better investment.
Dividend yield measures distributions relative to the ETF's share price. Total return also includes changes in the share price and reinvested distributions. Investors seeking income should compare trailing distribution yields and payment schedules, while long-term investors should evaluate total returns across different market conditions.
ETF distributions can change and are not guaranteed. A fund's yield should therefore be considered alongside its holdings, costs, and investment strategy.
Healthcare demand can remain relatively resilient, but healthcare ETFs are still equity investments. Their prices can fall when company earnings weaken, valuations decline, or industry conditions change.
Healthcare companies operate under extensive government and regulatory oversight. Changes in drug pricing rules, insurance coverage, reimbursement rates, and approval requirements can affect revenue and profitability.
Pharmaceutical companies may face pricing pressure, while insurers and healthcare providers can be affected by changes in government healthcare programs and medical reimbursement policies.
Drug manufacturers rely on successful research, regulatory approvals, and patent protection. When a major drug loses patent protection, generic competition can reduce sales and profit margins.
Biotechnology companies face additional uncertainty because clinical trials can fail, regulatory decisions can be delayed, and research programs often require substantial funding. These developments can cause sharp price movements in specialized biotechnology ETFs.
Concentration is another concern. A fund that relies heavily on a few large holdings may be affected disproportionately when one of those companies encounters financial or regulatory problems. Global funds also face currency and country-specific risks.
Healthcare ETFs can be suitable for long-term investors seeking exposure to pharmaceutical innovation, medical technology, biotechnology, and healthcare services. Demand for medical treatments and services is supported by factors such as aging populations and ongoing research.
However, long-term industry growth does not guarantee strong investment returns. Valuations, competition, regulation, and company performance still matter. Broad funds such as XLV and VHT can provide sector diversification, while specialized funds carry more concentrated risks.
Healthcare is often considered a defensive sector because many medical treatments and services remain necessary during economic downturns. However, healthcare ETFs can still decline during market sell-offs.
The level of resilience depends on the fund's holdings. Pharmaceutical and healthcare service companies may have different earnings patterns from biotechnology developers or medical device manufacturers. A healthcare ETF should not be treated as a guaranteed downside hedge.
Yes. Many healthcare ETFs distribute dividends from the income generated by their underlying holdings. However, distribution amounts, yields, and payment frequency vary by fund.
Investors seeking dividend income should compare trailing yields, distribution history, and the businesses generating the underlying income. A higher yield alone does not guarantee a more reliable income stream or better total returns.
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
Log In
Sign Up